×
About 4,950 results

ALLMedicine™ Polycythemia Vera Center

Research & Reviews  1,297 results

EBV-Gastritis Preceded the Development of Nasopharyngeal EBV (+) Diffuse Large B Cell L...
https://doi.org/10.1177/10668969221137525
International Journal of Surgical Pathology; Puello Yocum B, Mesa H et. al.

Feb 4th, 2023 - Epstein-Barr virus (EBV) is acquired early in life as asymptomatic or symptomatic infectious mononucleosis (IM) and remains latent in a few B cells in most individuals. Pathologic EBV-reactivation affects immunosuppressed individuals and manifests...

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
https://clinicaltrials.gov/ct2/show/NCT05210790

Feb 3rd, 2023 - Phase 3 study in approximately 250 subjects previously diagnosed with polycythemia vera (PV) who require phlebotomy on a routine basis. There is a 32-week period during which rusfertide or placebo will be added-on to each subject's ongoing therapy...

Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and eryt...
https://doi.org/10.1097/MOH.0000000000000747
Current Opinion in Hematology; Handa S, Ginzburg Y et. al.

Feb 3rd, 2023 - Development of hepcidin therapeutics has been a ground-breaking discovery in restoring iron homeostasis in several haematological disorders. The hepcidin mimetic, rusfertide, is in late-stage clinical development for treating polycythemia vera pat...

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-e...
https://clinicaltrials.gov/ct2/show/NCT03952039

Feb 2nd, 2023 - This Phase 3, multicenter, randomized, two-arm, open-label study will include subjects with intermediate or high-risk (as per the DIPSS score) primary myelofibrosis (PMF), postpolycythemia vera myelofibrosis (post-PV MF), or post-essential thrombo...

Erythrocytosis, Thrombocytosis and Rate of Recurrent Thromboembolic Event - A Populatio...
https://doi.org/10.1111/ejh.13938
European Journal of Haematology; Larsson AE, Andréasson B et. al.

Feb 2nd, 2023 - The management to reduce risk of thromboembolic complications in polycythemia vera and essential thrombocythemia are well established, but for other conditions with elevated hemoglobin, hematocrit or platelets there are no consensus regarding trea...

see more →

Guidelines  3 results

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.

Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Onco...
https://doi.org/10.6004/jnccn.2016.0169
Journal of the National Comprehensive Cancer Network : JN... Mesa R, Jamieson C et. al.

Dec 14th, 2016 - Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagn...

Prophylaxis and management of venous thromboembolism in patients with myeloproliferativ...
https://doi.org/10.1007/s00277-014-2224-8
Annals of Hematology; Kreher S, Ochsenreither S et. al.

Oct 14th, 2014 - Patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) like polycythemia vera and essential thrombocythemia are at increased risk of arterial and venous thrombosis. Strategies of prevention may consist of platelet aggreg...

see more →

Drugs  18 results see all →

Clinicaltrials.gov  137 results

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
https://clinicaltrials.gov/ct2/show/NCT05210790

Feb 3rd, 2023 - Phase 3 study in approximately 250 subjects previously diagnosed with polycythemia vera (PV) who require phlebotomy on a routine basis. There is a 32-week period during which rusfertide or placebo will be added-on to each subject's ongoing therapy...

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-e...
https://clinicaltrials.gov/ct2/show/NCT03952039

Feb 2nd, 2023 - This Phase 3, multicenter, randomized, two-arm, open-label study will include subjects with intermediate or high-risk (as per the DIPSS score) primary myelofibrosis (PMF), postpolycythemia vera myelofibrosis (post-PV MF), or post-essential thrombo...

A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis ...
https://clinicaltrials.gov/ct2/show/NCT04446650

Jan 20th, 2023 - The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This ...

CO-Rebreathing in Comparison to Isotopic Red Cell Volume Determination in the Diagnosis of Primitive and Secondary Polycythemia
https://clinicaltrials.gov/ct2/show/NCT03008642

Jan 19th, 2023 - The definition of a true polycythemia is stricto sensu an increased red cell mass (RCM) above 125% of the expected value depending on the size and the weight of the patient. However, this measurement requires an isotopic labeling of red cells and ...

Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors
https://clinicaltrials.gov/ct2/show/NCT05153343

Jan 18th, 2023 - Flonoltinib Maleate (FM) targets Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). FM is a dual target inhibitor of JAK2/FLT3.FM has the activity of inhibiting JAK2 signaling pathway, and pharmacodynamics evaluation also confirmed that ...

see more →

News  512 results

Innovations Are Poised to Lead MPN/MDS Treatment Landscape in a Positive Direction
https://www.onclive.com/view/innovations-are-poised-to-lead-mpn-mds-treatment-landscape-in-a-positive-direction

Nov 9th, 2022 - A full day of programming on hematologic malignancies will kick off the 40th Annual Chemotherapy Foundation Symposium. Included in the lineup highlighting advances in multiple myeloma, leukemias, lymphomas, and other issues across malignancies, a ...

European Commission Grants Orphan Drug Designation to Selinexor for Myelofibrosis
https://www.onclive.com/view/european-commission-grants-orphan-drug-designation-to-selinexor-for-myelofibrosis

Nov 1st, 2022 - The European Commission (EC) has granted an orphan drug designation to selinexor (Xpovio) for the treatment of patients with myelofibrosis.1 Selinexor, a first-in-class, oral XPO1 inhibitor, previously received an orphan drug designation for th...

Novel Interventions May Reduce Phlebotomy Use in Patients With Polycythemia Vera
https://www.onclive.com/view/novel-interventions-may-reduce-phlebotomy-use-in-patients-with-polycythemia-vera

Oct 20th, 2022 - Patients with polycythemia vera (PV), a myeloproliferative neoplasm associated with JAK2 mutations and overproduction of red blood cells, often require regular therapeutic phlebotomies to avoid thrombosis. The most common presentations of thrombos...

Rusfertide Leads to Promising Phlebotomy Reduction in Polycythemia Vera
https://www.onclive.com/view/rusfertide-leads-to-promising-phlebotomy-reduction-in-polycythemia-vera

Sep 30th, 2022 - Treatment with rusfertide (PTG-300) generated sustained hematocrit control at levels below 45% in patients with polycythemia vera (PV), leading to a reduced need for repeated phlebotomy and eliminating this need in some patients, according to find...

Dr. Kuykendall on Prognostication Factors in Myelofibrosis
https://www.onclive.com/view/dr-kuykendall-on-prognostication-factors-in-myelofibrosis

Sep 29th, 2022 - Andrew Kuykendall, MD, assistant member, the Department of Malignant Hematology, Moffitt Cancer Center, discusses the evolution of prognostication factors in primary and secondary myelofibrosis. The heterogeneous nature of myelofibrosis highlight...

see more →

Patient Education  13 results see all →